Gemtuzumab-Ozogamicin-Related Impaired Hemoglobin-Haptoglobin Scavenging as On-Target/Off-Tumor Toxicity of Anti-CD33 AML Therapy: A Report of Two Cases

Gemtuzumab-Ozogamicin-Related Impaired Hemoglobin-Haptoglobin Scavenging as On-Target/Off-Tumor Toxicity of Anti-CD33 AML Therapy: A Report of Two Cases

Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 antibody, which is conjugated to a cytotoxic calicheamicin. It is used to treat acute myeloid leukemia (AML) in combination with chemotherapy. We describe here two GO-treated acute myeloid leukemia (AML) cases: both patients suffered from a toxic s...

Full description

Saved in:
Bibliographic Details
Main Authors: Hanna L. M. Rajala, Veli-Jukka Anttila, Mikko Haapio, Mikko A. I. Keränen, Ulla Wartiovaara-Kautto, Riikka Räty
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2021/6641349
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items